Physician profile
Robert A Tester
NPI 1689783268
$11,274.17
in general payments reported to CMS, 2019-2025
21 companies · $389 in 2025
The $389 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,964 · 2020: $205 · 2021: $111 · 2022: $325 · 2023: $639 · 2024: $641 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,640.64 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $7,200.92 | 2019-2025 | Clareon, Acrysof Iq Panoptix Uv Iol, Clareon Panoptix Pro |
| Alcon Research LLC | $2,800.00 | 2019 | |
| Abbvie INC. | $198.99 | 2023-2025 | Lumigan, Durysta |
| Regeneron Healthcare Solutions, INC. | $180.07 | 2021-2024 | Eylea Hd |
| Carl Zeiss Meditec USA, INC. | $128.96 | 2023 | |
| Harrow Eye, LLC | $122.48 | 2024-2025 | Iheezo, Triesence |
| Bausch & Lomb Americas INC. | $91.41 | 2024-2025 | Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $87.09 | 2019 | |
| Thea Pharma INC. | $62.02 | 2024-2025 | Iyuzeh |
| Rxsight INC | $53.01 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $50.14 | 2021 | |
| Oyster Point Pharma, INC. | $46.94 | 2024-2025 | Tyrvaya |
| Biotissue Holdings INC. | $43.89 | 2022-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.86 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $39.60 | 2020-2024 | Tecnis Iol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $31.90 | 2025 | Oxervate |
| Sight Sciences, INC. | $29.49 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Biogen, INC. | $22.97 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $18.81 | 2025 | Xdemvy |
| Genentech USA, INC. | $13.19 | 2022 | |
| Alimera Sciences, INC. | $10.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.